CY1122121T1 - N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας - Google Patents

N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας

Info

Publication number
CY1122121T1
CY1122121T1 CY20191100951T CY191100951T CY1122121T1 CY 1122121 T1 CY1122121 T1 CY 1122121T1 CY 20191100951 T CY20191100951 T CY 20191100951T CY 191100951 T CY191100951 T CY 191100951T CY 1122121 T1 CY1122121 T1 CY 1122121T1
Authority
CY
Cyprus
Prior art keywords
pyridin
hemisulfate
compound
tetpahpo
diphthophophainyl
Prior art date
Application number
CY20191100951T
Other languages
English (en)
Inventor
Daniel Richard Roberts
Richard Raymond Schartman
Chenkou Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122121(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1122121T1 publication Critical patent/CY1122121T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αποκαλύπτεται ημιθειικό άλας της Ένωσης (I): και κρυσταλλικές μορφές του ημιθειικού άλατος. Επίσης αποκαλύπτονται μέθοδοι χρήσης του ημιθειικού άλατος της Ένωσης (I) ως ανταγωνιστή υποδοχέα CGRP και φαρμακευτικών συνθέσεων που περιλαμβάνουν το ημιθειικό άλας της Ένωσης (I). Το ημιθειικό άλας της Ένωσης (I) είναι χρήσιμο στην θεραπεία, αποτροπή ή ανακούφιση διαταραχών που συμπεριλαμβάνουν ημικρανία και άλλες κεφαλαλγίες, νευρογενή αγγειοδιαστολή, νευρογενή φλεγμονή, θερμική βλάβη, κυκλοφορικό σοκ, έξαψη που σχετίζεται με εμμηνόπαυση, φλεγμονώδεις ασθένειες της αναπνευστικής οδού, όπως άσθμα και χρόνια αποφρακτική πνευμονοπάθεια (COPD).
CY20191100951T 2012-02-27 2019-09-11 N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας CY1122121T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
PCT/US2013/027648 WO2013130402A1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt
EP13708603.9A EP2820016B1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Publications (1)

Publication Number Publication Date
CY1122121T1 true CY1122121T1 (el) 2020-11-25

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101052T CY1119448T1 (el) 2012-02-27 2017-10-10 N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ
CY20191100951T CY1122121T1 (el) 2012-02-27 2019-09-11 N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171101052T CY1119448T1 (el) 2012-02-27 2017-10-10 N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ

Country Status (26)

Country Link
US (1) US8759372B2 (el)
EP (2) EP2820016B1 (el)
JP (2) JP6208154B2 (el)
KR (2) KR102220969B1 (el)
CN (1) CN104136437B (el)
AU (1) AU2013226361B2 (el)
BR (1) BR112014021032B1 (el)
CA (1) CA2865585C (el)
CY (2) CY1119448T1 (el)
DK (2) DK3254681T3 (el)
EA (1) EA025358B1 (el)
ES (2) ES2746031T3 (el)
HK (1) HK1248111B (el)
HR (2) HRP20171620T1 (el)
HU (2) HUE034936T2 (el)
IL (1) IL234272B (el)
LT (2) LT3254681T (el)
MX (1) MX352171B (el)
NO (1) NO2935439T3 (el)
PL (2) PL3254681T3 (el)
PT (2) PT2820016T (el)
RS (2) RS59295B1 (el)
SG (1) SG11201404834XA (el)
SI (2) SI2820016T1 (el)
SM (1) SMT201700489T1 (el)
WO (1) WO2013130402A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
ES2746031T3 (es) * 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
EP4316595A3 (en) 2016-09-02 2024-04-17 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
CN115477679A (zh) * 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
SI4088720T1 (sl) * 2018-03-25 2026-01-30 Pfizer Ireland Pharmaceuticals Unlimited Company Rimegepant za motnje, povezane s cgrp
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト
WO2020252368A2 (en) * 2019-06-14 2020-12-17 The Regents Of The University Of California New therapeutic approach to lung disease
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor
WO2026074002A1 (en) 2024-10-02 2026-04-09 Krka, D.D., Novo Mesto Crystalline salts of rimegepant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
JPWO2005085228A1 (ja) 2004-03-05 2008-01-17 萬有製薬株式会社 シクロアルカノピリジン誘導体
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
AU2005299852B2 (en) 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
AU2007238894A1 (en) 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. Process for the preparation of pyridine heterocycle CGRP antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
ES2746031T3 (es) * 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato

Also Published As

Publication number Publication date
BR112014021032B1 (pt) 2022-09-27
HRP20171620T1 (hr) 2017-12-01
DK2820016T3 (da) 2017-11-13
LT3254681T (lt) 2019-09-25
EP2820016A1 (en) 2015-01-07
CN104136437B (zh) 2016-05-11
NO2935439T3 (el) 2018-03-31
SI3254681T1 (sl) 2019-10-30
JP6476253B2 (ja) 2019-02-27
SI2820016T1 (sl) 2017-11-30
KR20200016993A (ko) 2020-02-17
AU2013226361A1 (en) 2014-10-16
DK3254681T3 (da) 2019-09-30
KR20140130140A (ko) 2014-11-07
US8759372B2 (en) 2014-06-24
JP2015511581A (ja) 2015-04-20
EP2820016B1 (en) 2017-08-02
EP3254681A1 (en) 2017-12-13
HK1248111B (en) 2020-04-17
SMT201700489T1 (it) 2017-11-15
MX352171B (es) 2017-11-13
EA201491585A1 (ru) 2015-01-30
HUE047050T2 (hu) 2020-04-28
US20130225636A1 (en) 2013-08-29
LT2820016T (lt) 2017-10-25
EA025358B1 (ru) 2016-12-30
BR112014021032A2 (el) 2017-06-20
IL234272B (en) 2018-10-31
SG11201404834XA (en) 2014-09-26
KR102220969B1 (ko) 2021-02-25
EP3254681B1 (en) 2019-06-19
KR102076118B1 (ko) 2020-02-11
JP6208154B2 (ja) 2017-10-04
HUE034936T2 (hu) 2018-03-28
ES2642737T3 (es) 2017-11-17
AU2013226361B2 (en) 2017-09-21
CA2865585C (en) 2019-12-10
JP2017226693A (ja) 2017-12-28
CY1119448T1 (el) 2018-03-07
RS56556B1 (sr) 2018-02-28
PT3254681T (pt) 2019-10-01
CN104136437A (zh) 2014-11-05
PL3254681T3 (pl) 2019-12-31
WO2013130402A1 (en) 2013-09-06
CA2865585A1 (en) 2013-09-06
PT2820016T (pt) 2017-10-18
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
RS59295B1 (sr) 2019-10-31
HRP20191655T1 (hr) 2019-12-13
ES2746031T3 (es) 2020-03-04

Similar Documents

Publication Publication Date Title
CY1122121T1 (el) N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας
TN2012000139A1 (en) Cgrp receptor antagonists
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
AR048343A1 (es) Agentes terapeuticos para el tratamiento de la migrana
MX374401B (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso para tratar cancer.
PH12017500146A1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
AR080746A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida antagonista de receptores cgrp.
NO20054206L (no) Bifenylderivater
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
TW200628470A (en) Constrained compounds as CGRP-receptor antagonists
JO3754B1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
HK1210771A1 (zh) 氮杂吲哚衍生物
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
WO2007130860A3 (en) Constrained compounds as cgrp-receptor antagonists
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
MX350862B (es) Acidos de piperidinil naftilacetico.
NO20084564L (no) Stramme "Constrained" forbindelser som CGRP-reseptor antagonister
WO2007130927A3 (en) Condensed tricyclic compounds as cgrp-receptor antagonists
CL2009000248A1 (es) Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
WO2014147636A8 (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
CY1114902T1 (el) Ανταγωνιστες cgrp υποδοχεα
CO6331339A2 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3